KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other financing activities (2018 - 2025)

TherapeuticsMD's Other financing activities history spans 11 years, with the latest figure at $23000.0 for Q1 2025.

  • For Q1 2025, Other financing activities fell 79.28% year-over-year to $23000.0; the TTM value through Mar 2025 reached $298000.0, up 7.97%, while the annual FY2023 figure was $1.3 million, N/A changed from the prior year.
  • Other financing activities reached $23000.0 in Q1 2025 per TXMD's latest filing, down from $111000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.3 million in Q4 2023 to a low of -$1.1 million in Q3 2023.
  • Average Other financing activities over 5 years is $168300.0, with a median of $80500.0 recorded in 2021.
  • The largest YoY upside for Other financing activities was 274.35% in 2023 against a maximum downside of 251.85% in 2023.
  • A 5-year view of Other financing activities shows it stood at $228000.0 in 2021, then plummeted by 419.74% to -$729000.0 in 2022, then soared by 274.35% to $1.3 million in 2023, then tumbled by 91.27% to $111000.0 in 2024, then tumbled by 79.28% to $23000.0 in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Other financing activities are $23000.0 (Q1 2025), $111000.0 (Q1 2024), and $1.3 million (Q4 2023).